Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 7/20 | 0.39 |
| ▸ | MET | P08581 | 18/20 | 0.39 |
| ▸ | KDR | P35968 | 9/20 | 0.37 |
| ▸ | IGF1R | P08069 | 6/20 | 0.37 |
| ▸ | MERTK | Q12866 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461519 | 0.96 | AXL (0.38) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL2151233 | 0.88 | PLAU (0.39) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL3422130 | 0.88 | MET (0.52) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL374249 | 0.85 | AXL (0.42) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL2151613 | 0.85 | MET (0.36) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL377027 | 0.84 | MET (0.40) | AXLMETKDRMERTK | |
| SCHEMBL3418984 | 0.84 | AXL (0.42) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL2158756 | 0.83 | MET (0.54) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL3421428 | 0.82 | MET (0.35) | AXLMETKDRIGF1RMERTK | |
| SCHEMBL3419332 | 0.80 | MET (0.35) | AXLMETKDRIGF1RMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532657-B9 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-04-19 | — | — | EP | disclosed |
| EP-2532657-B1 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-08-31 | — | — | EP | disclosed |
| US-8426585-B2 | Compounds comprising a spiro-ring | Xi, Ning (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2012-12-13 | — | — | US | disclosed |
| EP-2532657-A2 | Compounds and methods of use | Sunshine Lake Pharma Co., Ltd (CN) | 2012-12-12 | — | — | EP | disclosed |
| US-8293897-B2 | Compounds comprising a spiro-ring and methods of use | Xi, Ning (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2340244-A1 | COMPOUNDS AND METHODS OF USE | Xi, Ning (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010045095-A1 | COMPOUNDS AND METHODS OF USE | XI NING (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | PRKDC, PRKACA, PRKX | AXL 719/4885MET 302/4885KDR 600/4885 |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | CDC42BPG, HRAS, PTPRJ | AXL 1146/4885MET 732/4885KDR 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.